fosfestrol and Thromboembolism

Due to an advanced prostatic carcinoma 166 patients were given a massive dose of oestrogen over a period of 10 days (6 g Honvan i.v.). A retrospective comparison of a control group of 94 patients without prophylaxis against thrombosis and a control group of 36 patients having received Heparin-Dihydergot did not show a significant difference of cardiovascular complications. Therefore, further 36 patients received a thrombocyte aggregation inhibitor (Godamed) as prophylaxis against embolic thrombosis. At the same time lung perfusion scintigraphy (99m Tc-Microspheres) was made directly before and after oestrogen therapy. Clinically and lung scintigraphically there was no different thromboembolic incidence compared to the patients given a Heparin-Dihydergot prophylaxis.

Topics: Aged; Anticoagulants; Antineoplastic Agents; Aspirin; Clinical Trials as Topic; Diethylstilbestrol; Dihydroergotamine; Drug Combinations; Glycine; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Platelet Aggregation; Prostatic Neoplasms; Retrospective Studies; Thromboembolism

Since 1972 in the Urology Department at Darmstadt Hospital the Honvan-high-dose-therapy of 130 patients with metastatic prostatic carcinoma has been carried out under standardizing condition. The analysis shows that there is no significant difference between the patients with prophylaxis against thrombosis (Macrodex and Dihydergot-Heparin) and without prophylaxis. The patients with anti-thrombotic prophylaxis demonstrated significantly higher incidence of reversible elevation of transaminases. The effect of Heparin is probably responsible for this.

Topics: Aged; Antineoplastic Agents; Diethylstilbestrol; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Retrospective Studies; Thromboembolism